
|Articles|September 15, 2002
Ocular bacterial treatment in development
Alameda, CA-InSite Vision Inc. and Bausch & Lomb have signed a licensing agree-ment to develop InSite's product ISV-403 for the treatment of ocular bacterial infections.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ophthalmology pipeline watch: Key trial results and PDUFA dates for Q1 2026
2
Ocugen publishes phase 1 GARDian1 gene therapy data for Stargardt disease
3
Ocugen releases positive preliminary 12-month data from phase 2 ArMaDa trial
4
Rayner announces Sophi Phaco System in the US
5














































